UK Panel Recommends Limited Prostate Cancer Screening for BRCA2 Carriers

The UK's National Screening Committee has recommended prostate cancer screening only for men who carry a BRCA2 gene variant and have a family history of breast, ovarian, pancreatic, or prostate cancer. The committee reviewed existing evidence and concluded that a wider screening program would likely cause more harm than benefit.

Current PSA testing can lead to treatment of slow-growing cancers that would not cause symptoms, resulting in side effects such as incontinence and impotence.

Under the new advice, eligible men should be screened every two years between ages 45 and 61. The committee did not extend screening to black men or to men with a family history of prostate cancer, citing insufficient trial data and risk of overdiagnosis.

Screening involves a genetic test to identify BRCA2 mutations. Around three in 1,000 men carry such variants, though many remain unaware without family testing.

Prostate cancer is the most common cancer among men in the UK, with 55,000 new diagnoses and 12,000 deaths recorded each year. The committee stated that the number of lives potentially saved by broader screening does not outweigh harms to healthy individuals.